Published in Cell on February 16, 2017
Doubling Down on Mutant RAS Can MEK or Break Leukemia. Cell (2017) 1.92
Genetics: Fitness depends on KRAS imbalance. Nat Rev Clin Oncol (2017) 0.75
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics (2009) 15.08
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature (2001) 10.56
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature (2014) 6.83
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med (2012) 4.05
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn (2015) 3.84
Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet (2001) 3.27
Dragging ras back in the ring. Cancer Cell (2014) 3.10
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.86
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Retroviral insertional mutagenesis: past, present and future. Oncogene (2005) 2.63
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood (2014) 2.54
Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature (2010) 2.51
Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell (1990) 2.16
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res (2010) 1.95
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One (2009) 1.94
Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci U S A (2006) 1.93
Doubling Down on Mutant RAS Can MEK or Break Leukemia. Cell (2017) 1.92
A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat Genet (2006) 1.79
Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood (1996) 1.77
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature (2009) 1.72
Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol (2006) 1.71
Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc Natl Acad Sci U S A (2009) 1.67
Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood (2010) 1.60
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature (2014) 1.55
Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. Blood (2002) 1.54
Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci U S A (2013) 1.27
Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A (2010) 1.25
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov (2014) 1.21
Oncogenic activating mutations are associated with local copy gain. Mol Cancer Res (2009) 1.21
Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. Proc Natl Acad Sci U S A (2013) 1.11
The biology and clinical impact of genetic lesions in myeloid malignancies. Blood (2013) 1.06
Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities. Nature (2016) 1.06
Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood (2014) 1.05
FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res (2016) 1.05
Reproducible pharmacogenomic profiling of cancer cell line panels. Nature (2016) 0.96